Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

(2013) Sven Wind et al.   CLINICAL PHARMACOKINETICS

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects

(2012) Sebastian Härtter et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

(2011) Peter Stopfer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

(2009) T. Tachibana et al.   XENOBIOTICA

The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies

(2008) SU Yasuda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE